Articles tagged with Cell Therapies
A new pouch device has been developed to protect transplanted human liver cells from immune systems for up to six months, producing crucial biomolecules. This breakthrough offers a potential path toward treating human diseases without needing to suppress the patient's immune system.
A phase Ib study found that combining sotorasib, a KRAS G12C inhibitor, with afatinib, a pan-ErbB tyrosine kinase inhibitor, showed antitumor activity in patients with KRAS-mutant non-small cell lung cancer. The combination demonstrated a high disease control rate and improved efficacy compared to prior therapies.
Researchers found that CAR-T cells require a high number of antigens to kill melanoma cells, but TCR-T cells are more effective in detecting and killing tumor cells with lower levels of target molecules. This study could lead to better immunotherapies for solid tumors.
Researchers comprehensively review T-cell responses to respiratory viral infections and chronic obstructive pulmonary disease (COPD), highlighting key characteristics of peptide-reactive T-cells. The review aims to improve understanding of the underlying mechanisms, leading to more effective immune protection and treatment methods.
Researchers have developed a new cancer photodrug that can treat deep-seated tumors more effectively and with reduced toxicity. Copper cysteamine photosensitizers allow the production of reactive oxygen species to kill cancer cells, minimizing damage to healthy cells.
Researchers at Mount Sinai have developed a novel therapy called MS67 that effectively fights acute myeloid leukemia with mixed lineage leukemia rearrangement. The therapy degrades the WDR5 protein, which drives the proliferation of this type of leukemia and other cancers such as pancreatic cancer.
A new study provides evidence supporting the involvement of aquaporins in corneal cell proliferation and nerve regeneration, suggesting AQP5 induction as a potential therapy to accelerate corneal defect resurfacing. The study found that AQP5 deficiency can slow down corneal epithelial repair, but its specific mechanism remained unclear.
Researchers have developed a novel immunotherapy approach using PBMCs to generate TEM/TCM cells for adoptive cell therapy in multiple myeloma. The treatment targets WT1-specific cytotoxic T lymphocytes, which show high sensitivity to MM cells, providing a promising basis for an additional therapeutic strategy.
New targeted therapies are being developed to target genetic alterations in cancer cells, such as the ARID1A mutation found in 10-50% of solid tumours. Early clinical trials suggest that these agents may be effective in treating multiple cancers, including breast, ovarian, and gastric cancer.
Researchers discovered that new mutations in the BRAF gene can lead to gliomas growing back after treatment, suggesting personalized approaches to therapy. The study also explored potential impacts of COVID-19 vaccines on menstruation.
A study by MedUni Wien researchers has discovered that the transcription factor BATF3 and its target genes play a crucial role in the growth of tumour cells in anaplastic large cell lymphoma. The findings suggest that targeting the IL-2R system could be an effective therapeutic approach, with promising results in animal models.
A team of researchers from IOCB Prague has discovered a new type of nanoparticles capable of safely transporting various types of nucleic acids used for therapeutic purposes into cells. The universal nature of their system sets it apart from existing solutions, allowing for efficient transport of mRNA and other RNA molecules into cells.
Scientists at City of Hope and Griffith University developed a novel anti-HIV protein called ZPAMt that can suppress HIV levels in the bone marrow, spleen, and brain of mice. The protein is delivered using exosomes, nanosized parts of cells that can reach difficult-to-access areas of the body.
A new trial run by UCL researchers shows promise in slowing the regrowth of tumors among some bowel cancer patients. The drug adavosertib was found to delay tumour growth by about two months on average and had relatively few side effects, particularly in left-sided/rectal tumours.
Researchers at MD Anderson Cancer Center presented new findings on novel therapeutic approaches, including cell therapy for solid tumors and antibody drug conjugates targeting TROP2. The therapies achieved partial responses in six patients, with an overall response rate of 35.3% and disease control rate of 70.6%.
A recent study found that amniotic fluid-derived, neonatal, and adult cells can be used to deliver long-lasting Factor VIII protein for Hemophilia A treatment. The researchers identified cells from umbilical cord tissue as the most promising candidates, which yielded high levels of Factor VIII mRNA and blood clotting activity.
Researchers at the University of Birmingham discovered that T cells send messages from five specific genes in their immune response to drugs given to treat skin cancer. This finding suggests that an optimal level of stimulation is required for a strong immune response, and blocking certain immune brakes may re-awaken dormant T cells.
Researchers develop a novel cell reprogramming strategy to transform glioma cells into non-proliferative neurons. This approach shows promise in slowing down the growth of GBMs and overcoming harmful side effects of conventional treatments.
Researchers developed lab-grown cochlear organoids to screen FDA-approved drugs for hair cell-inducing properties. The study identified Regorafenib as a potent stimulator of hair cell formation, even regenerating lost cells in mouse tissues.
Researchers at Max-Planck-Gesellschaft engineered synthetic exosomes that regulate cellular signaling during wound closure, leading to faster healing and improved formation of new blood vessels. The study provides a systematic understanding of extracellular vesicle communication and its potential therapeutic application.
Researchers have created a new technology to enhance therapeutic antibodies' ability to attack blood cancer cells by leveraging the human immune system. This approach combines IgM and IgG antibodies, resulting in a single molecule with increased complement activation.
Researchers at Thomas Jefferson University have discovered a drug cocktail that can mitigate disc degeneration associated with aging, reducing chronic back pain. By targeting senescent cells, the treatment slowed disc degeneration when administered early in life.
Researchers found that early life irradiation-induced γH2AX foci persisted in adult mice, leading to brain aging and shortened lifespan. The study suggests a potential link between early life radiation exposure and later-stage neurodegenerative disorders.
Isaac Hilton is using non-integrating episomal DNA viruses to create a new platform technology for cell and gene therapies. He aims to hijack these viruses to safely program medicinal functions in human cells.
The HIPGEN study, a multinational trial, investigates the efficacy and safety of allogeneic placenta-expanded adherent stromal cells to improve recovery after hip fracture arthroplasty. The trial aims to combat immobility and associated problems by strengthening periarticular hip musculature.
Patients with relapsed metastatic melanoma who received prior anti-PD-1 therapies had a lower response rate to adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL). ACT-TIL was less effective in these patients compared to those who had never received anti-PD-1 therapy. The study found that the objective response rate and ...
A CRISPR screening tool identified ZMYND8, an epigenetic regulatory protein, as a potential new therapeutic target for acute myeloid leukemia. Inhibiting ZMYND8 has been shown to leave cancer cells with smaller tumors and better survival in mouse models.
Researchers have developed heat-controllable CAR T cells that can target and destroy cancerous tumors, while preventing relapse. The cells are engineered to produce immunomodulators under photothermal control, increasing their effectiveness against solid tumors.
A study conducted at a Brazilian university found that treatment with curcumin and light reduces parasite load and eliminates Leishmania parasites completely. Curcumin showed good distribution in macrophages and reduced amastigotes' viability, changing their mitochondrial activity.
Researchers at the University of Pennsylvania School of Medicine have identified a new mechanism of resistance in advanced chronic lymphocytic leukemia (CLL) patients to CAR T cell therapy. They found that inhibiting the BET protein with the small molecule inhibitor JQ1 can reinvigorate exhausted T cells and increase their production.
Researchers at UC San Diego developed a cancer immunotherapy that pairs ultrasound with CAR T-cell therapy to destroy malignant tumors while sparing normal tissue. The therapy significantly slowed down tumor growth in mice and showed minimal on-target, off-tumor side effects.
A comprehensive molecular map of lung squamous cell carcinoma has identified potential new drug targets, including the gene NSD3, and highlighted immune regulation pathways that could help cancer evade immunotherapies. The study's findings have also revealed metabolic dysregulation and crosstalk between different cellular processes.
A new process for making RNA has been developed by researchers at the University of Massachusetts Amherst, yielding purer and more abundant RNA at a fraction of the cost. This breakthrough removes the largest stumbling block on the path to next-generation RNA therapeutic drugs.
Researchers identified molecular markers to purify unstable regulatory T cells, which can switch from protective to damaging function. Exposing these cells to a destabilizing environment also removes the unstable cells, leaving behind stable regulatory T cells for therapeutic use.
Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. The overall response rate to the treatment was 97%, while the complete response rate and progression-free survival rates were 67% and 77%, respectively.
Researchers at Trinity College Dublin and ONK Therapeutics are collaborating to optimize the metabolism of natural killer cells for enhanced anti-tumor functions. The project aims to address the immunosuppressive tumor microenvironment that impairs NK cell efficacy.
Researchers developed RADICA, a molecular rapid testing methodology for detecting viral nucleic acids in 40-60 minutes. The method has been tested on SARS-CoV-2 synthetic DNA/RNA and Epstein-Barr virus and shows high sensitivity and specificity.
Researchers designed cpLOV2 using circular permutation to simplify optogenetic device design. The new photoswitch maintained structural integrity and function, providing more choices for optogenetic application developments. It was successfully used to gate ORAI1 Ca2+ channel and control cell activities in a mouse model.
Researchers have made a significant breakthrough in immunotherapy design, using specifically designed receptors to completely clear brain cancer tumors in preclinical models. The approach has shown promise and could pave the way for new treatments for people with glioblastoma, an aggressive form of brain cancer.
Researchers discovered two subsets of tumor cells that can be targeted using different methods, one inducing ferroptosis and the other inhibiting antioxidant production. The study found that combining these approaches could improve treatment outcomes for small cell lung cancer patients.
Researchers have developed a new CAR T cell engineering technique that allows for the targeting of solid tumors without harming healthy cells. The technique uses ultrasensitive identification of HER2 protein on tumor cells and has shown promise in treating ovarian cancer.
Researchers found that tumor cells increase SLC6A14 expression levels in response to methionine deprivation, leading to increased AMPK activation. Targeting both SLC6A14 and AMPK may drive unbalanced metabolism in starved tumor cells, promoting apoptosis.
A significant number of NHL patients achieved complete remission and progression-free survival with Kymriah, a personalized cellular therapy. The study demonstrated the durability of this approach, with most patients remaining in remission five years after treatment.
The study found that cell turnover and cost of resistance are important factors impacting adaptive therapy success, with higher cell density and smaller pre-existing resistance levels doing better under adaptive conditions. Researchers developed a mathematical model to visualize the dynamics of cell populations and competition between ...
Researchers developed a CD45-directed antibody radioconjugate to target and deplete specific immune cells. The treatment safely depleted T cells, B cells, NK cells, and Tregs in mice while sparing red blood cells and platelets.
Australian researchers have discovered a new mechanism by which prostate cancer cells can adapt and evolve into more aggressive forms, making them resistant to treatment. The study highlights the importance of targeting microRNA-194 to slow down and inhibit the growth of prostate cancer models with neuroendocrine features.
Researchers at University of Texas M. D. Anderson Cancer Center discovered NIK protein essential for T cell metabolic shift during activation, regulating anti-tumor immunity. Elevated NIK activity in T cells may improve adoptive therapy efficacy.
A new consortium, Accelerating Research and Innovation for Advanced Therapies (ARDAT), aims to develop standardized models for predicting ATMP immunogenicity in humans. The €25.5 million project will also build understanding of ATMP drug metabolism within a host.
Researchers developed a novel photodynamic therapy to target insulin-producing lesions, showing promise in slowing tumor growth and inducing cell death. The treatment could provide a minimally invasive option for hyperinsulinemic hypoglycemia, improving patient management.
A new gelatin-based microcarrier offers significantly higher harvest rates of cells grown with over 90% compared to traditional standards. The microcarrier facilitates expansion of mesenchymal stromal cells used to treat various ailments, including heart attacks and immune system rejection.
Researchers have developed a computational approach called EpiMogrify that can predict the molecules needed to keep cells healthy in laboratory cultures. The model successfully identified molecules to maintain healthy nerve cells and heart cells, and predicted molecules that trigger stem cells to turn into specific cell types.
SMART researchers have discovered a new way to manufacture human red blood cells that cuts the culture time by half compared to existing methods. The new protocol stores cultured cells in liquid nitrogen for 11 days and produces RBCs within 11 days.
Researchers propose using nanomaterials to elevate oxygen levels in tumor tissues, reducing resistance to therapies. Additionally, therapeutic gas-generating and radical-generating nanomaterials can control oxygen delivery and induce cell death, offering new avenues for hypoxic tumor treatment.
Scientists create genetically engineered, off-the-shelf therapeutic T cells that can recognize and kill specific cancer cells without requiring personalized training. The 'off-the-shelf' approach solves limitations of original cell immunotherapy methods by avoiding time-consuming processes and resulting in more potent cells.
A clinical trial led by UNC Lineberger Comprehensive Cancer Center found CAR-T cell therapy to be highly active and safe in patients with relapsed/refractory Hodgkin lymphoma. The treatment resulted in a complete disappearance of tumor in the majority of patients and had an overall survival rate of 94% one year after treatment.
Researchers found that high levels of pre-treatment interleukin 6 indicate a high risk for neurotoxicity and cytokine release syndrome from CAR T therapy. The study also suggests that targeting the tumor microenvironment prior to therapy may help reduce inflammation and toxicities.
A new study by the University of Tokyo reveals that cell-laden hydrogel fibers with a diameter of 1.0 mm provide long-term immunoprotection and functionality for pancreatic cells in diabetic mice, outperforming thinner fibers.
A study published in Oncotarget reports that adoptive cell therapy in combination with checkpoint inhibitors improves T cell fold expansion and increases CD8 T cell tumor reactivity in patients with late-stage metastatic ovarian cancer. The authors suggest that combination immunotherapy may be a way forward for this purpose.
A new cell therapy approach has been shown to reduce the need for immunosuppression in kidney transplant recipients, thereby minimizing the risk of side effects. The study found that regulatory cells were just as safe as standard treatment and did not result in higher rejection rates.
Four critically ill COVID-19 patients improved significantly after receiving the experimental therapeutic CAP-1002, which contains cardiosphere-derived cells. The treatment helped reduce inflammation and showed no adverse effects, with all patients discharged from the hospital.